Andrii Siromolot

Dr. Andrii Siromolot

Technologies of Medical Diagnostics and Treatment, Taras Shevchenko National University of Kyiv, Kyiv, Kyyiv, Misto, Ukraine
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
DZDariia Zhukova
Dariia Zhukova
DKDaryna Katashynska
Daryna Katashynska
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
SRSvitlana Romaniuk
Svitlana Romaniuk
DKDenys Kolybo
Denys Kolybo
SKSerhiy Komisarenko
Serhiy Komisarenko

16 June 2026 in The Ukrainian Biochemical Journal
Verified
Journal Article
Open access
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
Mariia Ivanivna LobodaMariia Ivanivna Loboda
Mariia Ivanivna Loboda
SRS. I. Romaniuk
S. I. Romaniuk
ALA. J. Labyntsev
A. J. Labyntsev
IKI-M. M. Klymkovych
I-M. M. Klymkovych
DKD. V. Kolybo
D. V. Kolybo
Background. Breast cancer remains the leading cause of cancer mortality in women due to the resistance to chemotherapy and severe side effects of doxorubicin (Doxo). One of the approaches to overcome this problem is to search for phytocompounds that can enhance the efficacy of chemotherapy and prevent the development of side effects. Objective. This work aimed to investigate in vitro whether the polyphenol curcumin (Cur) from turmeric (Curcuma longa) in combination with the commercial drug Doxo-HCl can enhance the cytotoxic effect of Doxo on breast cancer cell lines MDA-MB-231 and MCF-7 and to exhibit chemoprotective activity against normal HEK-293 cells. Methods. Cell viability was assessed with MTT assay, apoptosis induction by flow cytometry with Annexin V–eGFP and PI, reactive oxygen species (ROS) generation by the DCFH-DA probe. The combination index (CI) calculation method and CompuSyn, Biosoft software were used to determine the synergism or antagonism of the components. Results. The study revealed dose-dependent cytotoxicity, increased ROS formation, and increased morphological aberrations in cells when using the combination of Cur with Doxo-HCl compared to Doxo-HCl. Cur acted as a chemosensitizer, which synergistically enhanced the antitumor activity of Doxo-HCl while simultaneously reducing its cytotoxic effects in normal cells by reducing ROS production. Conclusions. The use of Cur in combination with Doxo-HCl will likely reduce the effective therapeutic dose of Doxo and increase the effectiveness of breast cancer chemotherapy. Keywords: apoptosis, breast cancer cell lines, cell viability, chemosensitizer, combination index, combined treatment, curcumin, doxorubicin, oxidative stress

14 February 2026 in Biochimie
Verified
Journal Article
Closed access
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
DZDariia Zhukova
Dariia Zhukova
SRSvitlana Romaniuk
Svitlana Romaniuk
DKDenys Kolybo
Denys Kolybo
SKSerhiy Komisarenko
Serhiy Komisarenko

30 June 2025 in Biotechnologia Acta
Verified
Journal Article
Closed access
IGI.I. Gamaliia
I.I. Gamaliia
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
Cell-penetrating peptides (CPPs) facilitate efficient biomolecule delivery with low immunogenicity and cytotoxicity, making them ideal for in vivo drug delivery. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a ligand of the epidermal growth factor receptor (EGFR), is overexpressed in tumors and can promote angiogenesis. Doxorubicin (DOX), a chemotherapeutic, treats various cancers but has limited use with HB-EGF as a carrier. Aim. In this study we focused on the HB-EGF’s potential in enhancing DOX delivery and antitumor effects. Methods. Recombinant sHB-EGF was expressed in E. coli, purified by IMAC, and loaded with DOX with further dialysis of the complex from unbound antibiotics. Binding to cell surfaces (A431, 3T3, Vero), as well as ROS production using DCFH-DA, were analyzed by flow cytometry. Cell viability was assessed with MTT assays after 48 h. Results: sHB-EGF fluorescent derivatives effectively bound to A431 cells, enhancing DOX delivery to squamous-cell carcinoma and significantly reducing cell viability. Conclusions: HB-EGF efficiently delivers DOX into cells, suggesting its potential as a targeted drug carrier for EGFR/ErbB-1 overexpressed cancers.

17 August 2022 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
OROlena Rekalova
Olena Rekalova
OPOksana Panasiukova
Oksana Panasiukova
MPMarina Pogrebna
Marina Pogrebna
SYSvitlana Yasir
Svitlana Yasir
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
YFYuri Feschenko
Yuri Feschenko
Introduction. The development of effective test systems for tuberculosis (TB) diagnosis and the study of factors influencing their sensitivity and specificity constitute urgent tasks given the unstable epidemiological situation with TB in Ukraine and the world. The study aimed to determine the clinical and laboratory features of pulmonary TB that may affect the sensitivity of IgG TB antibody detection in human serum by the immuno-enzyme test system “IB-Chem Anti-Mycobacterium tuberculosis”, which was developed at the Palladin Institute of Biochemistry of the NAS of Ukraine and uses recombinant fusion protein MPT83-MPT63 as an antigen. Methods. Sera of 62 patients with chemoresistant pulmonary TB were tested for TB antibodies using an indirect enzyme-linked immunosorbent assay. Dependence of the obtained results on clinical symptoms and signs of pulmonary TB, the frequency of different types of antibiotic resistance, cellular and biochemical parameters of blood were analysed. Results. The sensitivity of the immuno-enzyme test system “IB-Chem Anti-Mycobacterium tuberculosis” for detecting human IgG TB antibodies using recombinant fusion protein MPT83-MPT63 was found to constitute 71.0%; it reached 81.3% in patients with destructive pulmonary TB. Conclusion. The developed test system should primarily be used for the TB diagnosis in patients with destructive changes in the lungs where the diagnostic efficiency of this test system reaches high indicators.

18 April 2026 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
Mariia Ivanivna LobodaMariia Ivanivna Loboda
Mariia Ivanivna Loboda
IRIvan Roman
Ivan Roman
GIGalyna Olexandrivna Iutynska
Galyna Olexandrivna Iutynska
ASAndrii Sylchuk
Andrii Sylchuk
Andrii SiromolotAndrii Siromolot
Andrii Siromolot
RMRuslan Mariychuk
Ruslan Mariychuk